Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(21 sites)
Belgium
Cliniques Universitaires Saint-Luc (CUSL), Brussels Germany
Universitätsklinikum Mannheim, Mannheim Cancer Center, Mannheim Italy
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" IRCCS IRST. S.r.l., Meldola, Forli-Cesena Fondazione del Piemonte per l'Oncologia Istituto di Candiolo IRCCS, Candiolo, Torino IRCCS Istituto Ortopedico Rizzoli, Bologna IRCCS Azienda Ospedaliero-Universitaria S. Orsola, Bologna Istituto Nazionale Tumori I.R.C.C.S- Fondazione G. Pascale, Naples Fondazione Policlinico Unversitario Campus Bio-Medico di Roma, Roma Netherlands
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL), Amsterdam Spain
Hospital de la Santa Creu i Sant Pau, Barcelona Hospital General Universitario Gregorio Maranon, Madrid Hospital Universitario Jimenez Diaz, Madrid Hospital General Universitario Gregorio Maranon, Madrid Hospital Universitario La Paz, Madrid Hospital Universitario y Politecnico La Fe, Valencia Hospital Universitario Miguel Servet, Zaragoza United Kingdom
Cambridge University Hospitals NHS Foundation Trust, Cambridge University College London Hospitals NHS Foundation Trust, London The Royal Marsden NHS Foundation Trust, London The Christie NHS Foundation Trust, Manchester